---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-022894"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:09:35.495594+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences Q3 revenue $7.4M, net loss $23.9M; discontinues PBCAR269A program

## Summary
- Net loss of $23.9M ($0.22 loss per share) vs $11.3M loss ($0.19) in Q3 2021.
- Revenue $7.4M, down 69% from $24M YoY; decrease primarily from absence of iECURE revenue.
- Cash $212.1M; expects runway to fund operations through end of 2024.
- Discontinued BCMA CAR T program PBCAR269A due to competitive landscape; no further clinical spending planned.
- Planned clinical update for azer-cel (PBCAR0191) and PBCAR19B in late Q4 2022 or early Q1 2023.

## SEC filing metadata
- accession: 0000950170-22-022894
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017022022894/0000950170-22-022894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017022022894/dtil-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-022894
- JSON: https://secwatch.observer/filing/0000950170-22-022894.json
- Plain text: https://secwatch.observer/filing/0000950170-22-022894.txt

## Key facts
- Earnings Releases
  PRECISION BIOSCIENCES INC reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 8, 2022, Precision BioSciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357874/000095017022022894/0000950170-22-022894-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.